Application of pedf in preparation of medicine for treating myeloproliferative diseases

A bone marrow proliferation and disease technology, applied in the application field of PEDF in the preparation of drugs for the treatment of myeloproliferative diseases, can solve the problems of inability to reduce the JAK2 gene mutation load, thrombocytopenia, etc., to reduce peripheral blood, inhibit proliferation, and reduce mortality Effect

Active Publication Date: 2022-04-15
XUZHOU MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, although targeted drugs such as the JAK inhibitor ruxolitinib have shown good symptoms in reducing spleen size and systemic symptoms, ruxolitinib cannot reduce the JAK2 gene mutation load, and may cause anemia and thrombocytopenia. Adverse reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pedf in preparation of medicine for treating myeloproliferative diseases
  • Application of pedf in preparation of medicine for treating myeloproliferative diseases
  • Application of pedf in preparation of medicine for treating myeloproliferative diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Reference attached figure 1 The results of enzyme-linked immunosorbent assay and Western blot detection on MPN mice after modeling showed that the expression of PEDF in plasma and bone marrow cells of MPN mice decreased. A: Concentration of PEDF in plasma of control group and MPN mice; B, C: Expression of PEDF protein in bone marrow mononuclear cells of control group and MPN mice. (n=3, *P<0.05)

Embodiment 2

[0034] Reference attached figure 2, MPN mice (n=7) were intervened with PBS or PEDF for 8 weeks, 4 mice given PBS died, and 1 mouse given PEDF died. According to the results of the survival rate, compared with the MPN mice in the control solvent PBS group, the death rate of the MPN mice in the PEDF group decreased, indicating that the PEDF treatment prolongs the survival time of the MPN mice.

Embodiment 3

[0036] Reference attached image 3 , MPN mice were treated with PBS / PEDF for five weeks, and blood was collected from the tail vein every week. The results of hemocytometer showed that compared with the MPN mice treated with PBS, the WBC, RBC, HCT, PLT decreased, indicating that the infusion of PEDF reduced the peripheral blood of MPN mice. The average values ​​of peripheral blood of mice in each group are shown in Table 1.

[0037] Table 1

[0038]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses the application of PEDF in the preparation of drugs for the treatment of myeloproliferative diseases. The research of the invention finds that PEDF can promote the proliferation of normal hematopoietic stem cells in MPN mice, inhibit the proliferation of tumor cells, reduce peripheral blood images, and reduce mortality. PEDF It can be used as a potential drug for the treatment of myeloproliferative diseases.

Description

technical field [0001] The invention belongs to the technical field of drugs for treating myeloproliferative diseases, and in particular relates to the application of PEDF in the preparation of drugs for treating myeloproliferative diseases. Background technique [0002] Myeloproliferative neoplasms (MPNs) are clonal hematopoietic disorders characterized by overproduction of differentiated hematopoietic cells in the chronic phase. Clinical manifestations are hemocytosis of one or more lineages of peripheral blood, often accompanied by hepatosplenomegaly Large, thrombosis and extramedullary hematopoiesis, classic myeloproliferative disorders refer to Ph chromosome-negative myeloproliferative neoplasms, mainly including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF ). Myeloproliferative neoplasms can transform into myelofibrosis or acute leukemia in the advanced stage of the disease, and bone marrow transplantation is currently the only curable ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/18A61P7/00A61P35/00
CPCA61K38/18A61P7/00A61P35/00
Inventor 曾令宇高慧付春玲鞠文李艳杰乔建林
Owner XUZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap